

April W Armstrong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5694455/publications.pdf>

Version: 2024-02-01

206
papers

13,342
citations

31949

53
h-index

26591

107
g-index

220
all docs

220
docs citations

220
times ranked

10201
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. JAMA - Journal of the American Medical Association, 2020, 323, 1945. | 3.8 | 953 |
| 2 | Psoriasis. Lancet, The, 2021, 397, 1301-1315. | 6.3 | 792 |
| 3 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071. | 2.9 | 726 |
| 4 | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal of Medicine, 2015, 373, 1318-1328. | 13.9 | 656 |
| 5 | Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 2014, 70, 512-516. | 0.6 | 650 |
| 6 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatorâ€“controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology, 2017, 76, 418-431. | 0.6 | 554 |
| 7 | Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine, 2016, 375, 422-434. | 13.9 | 530 |
| 8 | Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. Journal of the American Academy of Dermatology, 2013, 68, 654-662. | 0.6 | 327 |
| 9 | Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States. JAMA Dermatology, 2013, 149, 1180. | 2.0 | 327 |
| 10 | Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Metaâ€“Analysis of Observational Studies. Journal of the American Heart Association, 2013, 2, e000062. | 1.6 | 324 |
| 11 | Psoriasis and the Risk of Diabetes Mellitus. JAMA Dermatology, 2013, 149, 84. | 2.0 | 262 |
| 12 | Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet, The, 2019, 394, 831-839. | 6.3 | 250 |
| 13 | Videos to influence: a systematic review of effectiveness of video-based education in modifying health behaviors. Journal of Behavioral Medicine, 2014, 37, 218-233. | 1.1 | 246 |
| 14 | Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 411. | 2.0 | 241 |
| 15 | Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003â€“2011. PLoS ONE, 2012, 7, e52935. | 1.1 | 235 |
| 16 | Psoriasis and smoking: a systematic review and metaâ€“analysis. British Journal of Dermatology, 2014, 170, 304-314. | 1.4 | 199 |
| 17 | The association between psoriasis and hypertension. Journal of Hypertension, 2013, 31, 433-443. | 0.3 | 175 |
| 18 | US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. American Journal of Clinical Dermatology, 2016, 17, 87-97. | 3.3 | 173 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258. | 2.0 | 169 |
| 20 | Antidrug antibodies in psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2014, 170, 261-273. | 1.4 | 143 |
| 21 | Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. <i>Journal of Dermatological Science</i> , 2011, 63, 1-9. | 1.0 | 140 |
| 22 | Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498. | 6.3 | 139 |
| 23 | From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298. | 0.6 | 137 |
| 24 | The association between psoriasis and dyslipidaemia: a systematic review. <i>British Journal of Dermatology</i> , 2013, 168, 486-495. | 1.4 | 130 |
| 25 | Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985-2010. <i>PLoS ONE</i> , 2011, 6, e17520. | 1.1 | 129 |
| 26 | Psoriasis and suicidality: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 425-440.e2. | 0.6 | 117 |
| 27 | Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007394. | 1.3 | 115 |
| 28 | A tale of two plaques: convergent mechanisms of T cell-mediated inflammation in psoriasis and atherosclerosis. <i>Experimental Dermatology</i> , 2011, 20, 544-549. | 1.4 | 114 |
| 29 | Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , 2018, 154, 934. | 2.0 | 112 |
| 30 | Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. <i>British Journal of Dermatology</i> , 2011, 165, 1162-1168. | 1.4 | 110 |
| 31 | JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7. | 0.9 | 102 |
| 32 | Effects of video-based, online education on behavioral and knowledge outcomes in sunscreen use: A randomized controlled trial. <i>Patient Education and Counseling</i> , 2011, 83, 273-277. | 1.0 | 97 |
| 33 | Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 2219-2229. | 13.9 | 93 |
| 34 | Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy. <i>PLoS ONE</i> , 2012, 7, e33486. | 1.1 | 92 |
| 35 | Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography. <i>American Journal of Cardiology</i> , 2012, 109, 976-980. | 0.7 | 90 |
| 36 | Online video improves clinical outcomes in adults with atopic dermatitis: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 502-507. | 0.6 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2â€”Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. Journal of the American Academy of Dermatology, 2021, 84, 1254-1268. | 0.6 | 88 |
| 38 | Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Archives of Dermatological Research, 2018, 310, 271-319. | 1.1 | 84 |
| 39 | State of teledermatology programs in the United States. Journal of the American Academy of Dermatology, 2012, 67, 939-944. | 0.6 | 81 |
| 40 | Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review. Current Pharmaceutical Design, 2014, 20, 513-528. | 0.9 | 80 |
| 41 | An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS ONE, 2017, 12, e0181039. | 1.1 | 79 |
| 42 | Psoriasis and Hypertension Severity: Results from a Case-Control Study. PLoS ONE, 2011, 6, e18227. | 1.1 | 78 |
| 43 | Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology, 2012, 225, 121-126. | 0.9 | 77 |
| 44 | Practice Models and Challenges in Teledermatology: A Study of Collective Experiences from Teledermatologists. PLoS ONE, 2011, 6, e28687. | 1.1 | 73 |
| 45 | Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment, 2020, 31, 606-614. | 1.1 | 72 |
| 46 | Maintenance of clinical response and consistent safety profile with up to 3Âyears of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology, 2020, 82, 936-945. | 0.6 | 71 |
| 47 | Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 2018, 78, 383-394. | 0.6 | 69 |
| 48 | The global burden of psoriatic skin disease. British Journal of Dermatology, 2015, 172, 1665-1668. | 1.4 | 64 |
| 49 | A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). Journal of Investigative Dermatology, 2020, 140, 1784-1793.e2. | 0.3 | 61 |
| 50 | Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Journal of Dermatological Treatment, 2014, 25, 401-408. | 1.1 | 59 |
| 51 | Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. Dermatologic Clinics, 2012, 30, 113-124. | 1.0 | 58 |
| 52 | Safety of guselkumab in patients with moderateâ€toâ€severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <sc>VOYAGE</sc> 1 and <sc>VOYAGE</sc> 2 studies. British Journal of Dermatology, 2019, 180, 1039-1049. | 1.4 | 57 |
| 53 | Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Review of Clinical Immunology, 2013, 9, 949-958. | 1.3 | 56 |
| 54 | Effect of tonsillectomy on psoriasis: A systematic review. Journal of the American Academy of Dermatology, 2015, 72, 261-275. | 0.6 | 56 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1093-1104. | 1.6 | 55 |
| 56 | Antibiotic Resistance in Acne Treatment. <i>JAMA Dermatology</i> , 2017, 153, 810. | 2.0 | 54 |
| 57 | Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 665-669. | 0.6 | 51 |
| 58 | Does class attendance matter? Results from a second-year medical school dermatology cohort study. <i>International Journal of Dermatology</i> , 2015, 54, 807-816. | 0.5 | 51 |
| 59 | Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. <i>Rheumatology International</i> , 2017, 37, 97-105. | 1.5 | 48 |
| 60 | RAC1 activation drives pathologic interactions between the epidermis and immune cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 2661-2677. | 3.9 | 48 |
| 61 | Portable video media for presenting informed consent and wound care instructions for skin biopsies: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2010, 163, 1014-1019. | 1.4 | 47 |
| 62 | Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2016, 152, 661. | 2.0 | 46 |
| 63 | Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 906-917. | 0.6 | 45 |
| 64 | Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 968-977.e2. | 0.6 | 43 |
| 65 | National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716. | 0.6 | 43 |
| 66 | Standardizing Training for Psoriasis Measures. <i>JAMA Dermatology</i> , 2013, 149, 577. | 2.0 | 42 |
| 67 | Dermatologists in social media: A study on top influencers, posts, and user engagement. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1452-1455. | 0.6 | 42 |
| 68 | Teledermatology Operational Considerations, Challenges, and Benefits: The Referring Providers' Perspective. <i>Telemedicine Journal and E-Health</i> , 2012, 18, 580-584. | 1.6 | 41 |
| 69 | Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137. | 2.0 | 41 |
| 70 | Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 500-512. | 0.9 | 41 |
| 71 | Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905. | 1.4 | 40 |
| 72 | A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 329-336. | 3.3 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1037-1044. | 0.3 | 37 |
| 74 | Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 Phase III VOYAGE 1 and VOYAGE 2 Studies. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 155-164. | 3.3 | 37 |
| 75 | Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 395-402. | 0.6 | 36 |
| 76 | Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581. | 0.6 | 36 |
| 77 | Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. <i>British Journal of Dermatology</i> , 2019, 181, 967-975. | 1.4 | 34 |
| 78 | Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (<sc>NHANES</sc>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1109-1112. | 1.3 | 33 |
| 79 | Relationship between psoriasis and metabolic syndrome: a systematic review. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 663-677. | 0.8 | 31 |
| 80 | Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 383-391.e1. | 0.6 | 30 |
| 81 | Evaluation and Comparison of Store-and-Forward Teledermatology Applications. <i>Telemedicine Journal and E-Health</i> , 2010, 16, 424-438. | 1.6 | 29 |
| 82 | A Review of Health Outcomes in Patients with Psoriasis. <i>Dermatologic Clinics</i> , 2012, 30, 61-72. | 1.0 | 28 |
| 83 | From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 798-805.e7. | 0.6 | 28 |
| 84 | Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1325-1333. | 0.9 | 27 |
| 85 | Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1312-1316. | 1.3 | 26 |
| 86 | Public perception of dermatologists and comparison with other medical specialties: Results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 875-881. | 0.6 | 26 |
| 87 | Harnessing the Power of Crowds. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 405-416. | 3.3 | 25 |
| 88 | Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group. <i>Journal of Rheumatology</i> , 2014, 41, 2306-2314. | 1.0 | 25 |
| 89 | Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 691-699. | 3.3 | 25 |
| 90 | Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. <i>BMC Dermatology</i> , 2018, 18, 4. | 2.1 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890. | 3.3 | 24 |
| 92 | Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis. <i>Dermatology and Therapy</i> , 2022, 12, 1181-1196. | 1.4 | 24 |
| 93 | Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 327-332. | 1.3 | 23 |
| 94 | Do TNF Inhibitors Reduce the Risk of Myocardial Infarction in Psoriasis Patients?. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2043. | 3.8 | 22 |
| 95 | Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. <i>PLoS ONE</i> , 2019, 14, e0210517. | 1.1 | 22 |
| 96 | Long-Term Benefit/Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 167-184. | 1.4 | 22 |
| 97 | Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 79-86. | 3.3 | 21 |
| 98 | Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. <i>RMD Open</i> , 2019, 5, e000867. | 1.8 | 21 |
| 99 | Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 740-746. | 0.6 | 20 |
| 100 | Characteristics of Medical Liability Claims Against Dermatologists From 1991 Through 2015. <i>JAMA Dermatology</i> , 2018, 154, 160. | 2.0 | 20 |
| 101 | Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>American Journal of Clinical Dermatology</i> , 2018, 19, 879-886. | 3.3 | 20 |
| 102 | Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. <i>Journal of Dermatological Treatment</i> , 2019, 30, 27-34. | 1.1 | 20 |
| 103 | Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 748-757. | 0.6 | 20 |
| 104 | Misconceptions of photoprotection in skin of color. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, S9-S17. | 0.6 | 20 |
| 105 | Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, S1-S8. | 0.6 | 20 |
| 106 | Why Some Dermatologists Do Not Practice Store-and-Forward Teledermatology. <i>Archives of Dermatology</i> , 2012, 148, 649-50. | 1.7 | 18 |
| 107 | Power of crowdsourcing: Novel methods of data collection in psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1273-1281.e9. | 0.6 | 18 |
| 108 | Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 674-678. | 1.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 91-97. | 1.6 | 18 |
| 110 | Psoriasis and Sexual Behavior in Men: Examination of the National Health and Nutrition Examination Survey (NHANES) in the United States. <i>Journal of Sexual Medicine</i> , 2014, 11, 401-410. | 0.3 | 17 |
| 111 | Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324. | 1.1 | 17 |
| 112 | Managing Patients With Psoriasis in the Busy Clinic. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 196-206. | 0.6 | 16 |
| 113 | Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. <i>Archives of Dermatological Research</i> , 2013, 305, 891-897. | 1.1 | 15 |
| 114 | Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. <i>Clinical Drug Investigation</i> , 2017, 37, 493-501. | 1.1 | 15 |
| 115 | Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 454-460. | 1.1 | 15 |
| 116 | Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 1-11. | 3.3 | 15 |
| 117 | Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. <i>JAMA Dermatology</i> , 2022, 158, 252. | 2.0 | 15 |
| 118 | Psoriasis and Sexual Behavior in U.S. Women: An Epidemiologic Analysis Using the National Health and Nutrition Examination Survey (NHANES). <i>Journal of Sexual Medicine</i> , 2013, 10, 326-332. | 0.3 | 14 |
| 119 | Are patients comprehending? A critical assessment of online patient educational materials. <i>Journal of Dermatological Treatment</i> , 2018, 29, 295-299. | 1.1 | 14 |
| 120 | Economic burden of cutaneous infections in children and adults with atopic dermatitis. <i>Pediatric Dermatology</i> , 2019, 36, 303-310. | 0.5 | 14 |
| 121 | An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis. <i>Current Medicinal Chemistry</i> , 2015, 22, 1930-1942. | 1.2 | 14 |
| 122 | Comparative Prevalence of Complementary and Alternative Medicine Use Among Outpatients in Dermatology and Primary Care Clinics. <i>JAMA Dermatology</i> , 2014, 150, 1363. | 2.0 | 13 |
| 123 | Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation. <i>Journal of Dermatological Treatment</i> , 2018, 29, 329-333. | 1.1 | 13 |
| 124 | Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey. <i>Dermatology and Therapy</i> , 2022, 12, 1055-1064. | 1.4 | 13 |
| 125 | Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 200-205. | 1.1 | 12 |
| 126 | Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930. | 0.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , 2021, 32, 455-459. | 1.1 | 11 |
| 128 | Economic Burden of Chronic Hand Eczema: A Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 287-300. | 3.3 | 11 |
| 129 | The global burden of disease associated with alopecia areata. <i>British Journal of Dermatology</i> , 2015, 172, 1424-1426. | 1.4 | 10 |
| 130 | Perceptions of Aesthetic Outcome of Linear vs Multiple Z-Plasty Scars in a National Survey. <i>JAMA Facial Plastic Surgery</i> , 2016, 18, 263-267. | 2.2 | 10 |
| 131 | Using qualitative methods to understand factors contributing to patient satisfaction among dermatology patients: a systematic review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 290-294. | 1.1 | 10 |
| 132 | Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165. | 0.9 | 10 |
| 133 | Dermal suture only versus layered closure: A randomized, split wound comparative effectiveness trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1346-1352. | 0.6 | 10 |
| 134 | Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623. | 1.1 | 10 |
| 135 | Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702. | 1.0 | 9 |
| 136 | Quality of life among dermatology patients: a systematic review of investigations using qualitative methods. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 72-78. | 0.8 | 9 |
| 137 | Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740. | 1.4 | 9 |
| 138 | Updates in Rosacea: Epidemiology, Risk Factors, and Management Strategies. <i>Current Dermatology Reports</i> , 2014, 3, 23-28. | 1.1 | 8 |
| 139 | Effectiveness of a novel interactive health care education tool on clinical outcomes and quality of life in acne patients: A randomized controlled pilot study. <i>Journal of Dermatological Treatment</i> , 2015, 26, 435-439. | 1.1 | 8 |
| 140 | International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-960. | 1.0 | 8 |
| 141 | Development and psychometric evaluation of the self-assessment of psoriasis symptoms (SAPS) â€“ clinical trial and the SAPS â€“ real world patient-reported outcomes. <i>Journal of Dermatological Treatment</i> , 2017, 28, 505-514. | 1.1 | 8 |
| 142 | Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, , 1-4. | 1.1 | 8 |
| 143 | A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 823-828. | 0.6 | 7 |
| 144 | Suicidality among psoriasis patients: a critical evidence synthesis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 56-63. | 0.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey. <i>Advances in Therapy</i> , 2022, 39, 2657-2667. | 1.3 | 7 |
| 146 | Crowdsourcing for data collection: a pilot study comparing patient-reported experiences and clinical trial data for the treatment of seborrheic dermatitis. <i>Skin Research and Technology</i> , 2013, 19, 55-57. | 0.8 | 6 |
| 147 | Effect of a Pre-Treatment Educational Video in Improving Patient Satisfaction with 5-Fluorouracil Treatment for Actinic Keratoses: A Randomized Controlled Trial. <i>Dermatology and Therapy</i> , 2016, 6, 675-681. | 1.4 | 6 |
| 148 | Reply to: "Comment on "Dermatologists in social media: A study on top influencers, posts, and user engagement". <i>Journal of the American Academy of Dermatology</i> , 2022, 86, e51. | 0.6 | 6 |
| 149 | A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. <i>Dermatology and Therapy</i> , 2022, 12, 787-800. | 1.4 | 6 |
| 150 | Economics of Tele dermatology "Does the Math Add Up?. <i>JAMA Dermatology</i> , 2021, 157, 27. | 2.0 | 5 |
| 151 | Anogenital warts and relationship to child sexual abuse: Systematic review and meta-analysis. <i>Pediatric Dermatology</i> , 2021, 38, 842-850. | 0.5 | 5 |
| 152 | Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records. <i>Dermatology and Therapy</i> , 2021, 11, 1733-1749. | 1.4 | 5 |
| 153 | Bullous Dermatoses and Depression. <i>JAMA Dermatology</i> , 2021, 157, 1487. | 2.0 | 5 |
| 154 | Novel approach to utilizing electronic health records for dermatologic research: developing a multi-institutional federated data network for clinical and translational research in psoriasis and psoriatic arthritis. <i>Dermatology Online Journal</i> , 2012, 18, 2. | 0.2 | 5 |
| 155 | Development of a core outcome set for basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 573-581. | 0.6 | 5 |
| 156 | Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. <i>Journal of Dermatological Treatment</i> , 2020, 31, 452-459. | 1.1 | 4 |
| 157 | An association between hidradenitis suppurativa and HIV. <i>British Journal of Dermatology</i> , 2020, 182, 490-491. | 1.4 | 4 |
| 158 | Association Between the Mental Health of Patients With Psoriasis and Their Satisfaction With Physicians. <i>JAMA Dermatology</i> , 2020, 156, 754. | 2.0 | 4 |
| 159 | International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2022, 238, 430-437. | 0.9 | 4 |
| 160 | Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 2147-2157. | 1.4 | 4 |
| 161 | Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. <i>Dermatology Online Journal</i> , 2015, 21, . | 0.2 | 4 |
| 162 | Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. <i>Dermatology Online Journal</i> , 2020, 26, . | 0.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. <i>Dermatology and Therapy</i> , 2022, 12, 195-202. | 1.4 | 4 |
| 164 | Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologistsâ€™ Perspective: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2204-2210. | 1.0 | 3 |
| 165 | Patient-Centered Outcomes in Dermatology. <i>Current Dermatology Reports</i> , 2015, 4, 15-19. | 1.1 | 3 |
| 166 | Wound eversion versus planar closure for wounds on the face or neck: A randomized split-wound comparative effectiveness trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1439-1440. | 0.6 | 3 |
| 167 | Words matter: a randomized controlled study evaluating the impact of decisionâ€™ framing on treatment preferences in adults with psoriasis and psoriatic arthritis. <i>British Journal of Dermatology</i> , 2021, 184, 971-973. | 1.4 | 3 |
| 168 | Mental health outcomes and their association to race and ethnicity in acne patients: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 140-142. | 0.6 | 3 |
| 169 | Mental health outcomes in White patients versus patients with skin of color with psoriasis. <i>Dermatology Online Journal</i> , 2021, 27, . | 0.2 | 3 |
| 170 | Comparing the Effectiveness of Automated Online Counseling to Standard Web-Based Education on Improving Acne Knowledge: A Randomized Controlled Trial. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 55-60. | 3.3 | 2 |
| 171 | Association of Touch Avoidance with Disease Severity and Quality of Life in Psoriasis Patients. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 57-63. | 0.3 | 2 |
| 172 | Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 330-336. | 0.6 | 2 |
| 173 | Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. <i>Archives of Dermatological Research</i> , 2019, 311, 453-460. | 1.1 | 2 |
| 174 | Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 133-142. | 0.3 | 2 |
| 175 | Language proficiency and biologics access: a population study of psoriasis patients in the United States. <i>Journal of Dermatological Treatment</i> , 2020, , 1-5. | 1.1 | 2 |
| 176 | Response to Letter to the Editor â€™Reply to â€™ Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagementâ€™ Dermatologist Influencers on TikTokâ€™. <i>Journal of the American Academy of Dermatology</i> , 2021, , . | 0.6 | 2 |
| 177 | Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 40-43. | 1.0 | 2 |
| 178 | Oral small molecules for psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 163-166. | 1.6 | 2 |
| 179 | Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 28-32. | 1.0 | 2 |
| 180 | Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Exploring Mental Disorders in Patients With Skin Diseases. <i>JAMA Dermatology</i> , 2019, 155, 660. | 2.0 | 1 |
| 182 | Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 129-138. | 0.3 | 1 |
| 183 | GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations. <i>Journal of Rheumatology</i> , 2021, , jrheum.201670. | 1.0 | 1 |
| 184 | Differences in acne therapy prescribing patterns between dermatologists and pediatricians: A population-based study. <i>Pediatric Dermatology</i> , 2021, 38, 1150-1156. | 0.5 | 1 |
| 185 | A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. <i>Journal of Medical Internet Research</i> , 2021, 23, e29511. | 2.1 | 1 |
| 186 | Chronic spontaneous urticaria: a 16-year analysis of pediatric patient demographics, treatment patterns, and comorbidities. <i>Dermatology Online Journal</i> , 2021, 27, . | 0.2 | 1 |
| 187 | Topical opioid use in dermatologic disease: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e15150. | 0.8 | 1 |
| 188 | Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. <i>Journal of Dermatological Treatment</i> , 0, , 1-9. | 1.1 | 1 |
| 189 | Innovations in teledermatology: direct patient "specialist care enabled by mobile technology. <i>Expert Review of Dermatology</i> , 2012, 7, 223-225. | 0.3 | 0 |
| 190 | Response to: "œls tonsillectomy a therapeutic option for plaque-type psoriasis?" <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e155. | 0.6 | 0 |
| 191 | Screening Recommendations for Hepatitis B Virus Infection. <i>JAMA Dermatology</i> , 2016, 152, 565. | 2.0 | 0 |
| 192 | Response to Letter to the Editor commenting on: "œ Dermatologists in social media: A study on top influencers, posts, and user engagement" <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e165. | 0.6 | 0 |
| 193 | Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities. <i>Journal of Dermatological Treatment</i> , 2021, , 1-3. | 1.1 | 0 |
| 194 | Childhood atopic dermatitis: outpatient visit trends, demographics, and topical agents in the United States, 1995"2015. <i>International Journal of Dermatology</i> , 2021, 60, e423-e424. | 0.5 | 0 |
| 195 | Non-Medical Switching Impact on Patients and Providers " Psoriatic Disease Community Taking a Stand. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 126-127. | 0.3 | 0 |
| 196 | Opiate use in dermatology: A population-based study using the National Ambulatory Medical Care Survey in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 174-176. | 0.6 | 0 |
| 197 | Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. <i>International Journal of Dermatology</i> , 2022, 61, . | 0.5 | 0 |
| 198 | Trichotillomania in the United States: An epidemiologic study of patient characteristics, comorbidities, and treatment patterns. <i>Dermatology Online Journal</i> , 2021, 27, . | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. Journal of Investigative Dermatology, 2021, 141, 2539-2541. | 0.3 | 0 |
| 200 | Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. Journal of Investigative Dermatology, 2022, 142, 2026-2029.e4. | 0.3 | 0 |
| 201 | Re-Classification of Psoriasis Severity: Perspectives and Controversy. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 7-8. | 0.3 | 0 |
| 202 | Are we contributing to the opioid epidemic? A systematic review on systemic opioid use in dermatology. International Journal of Dermatology, 2021, , . | 0.5 | 0 |
| 203 | 2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations. Journal of Rheumatology, 2022, , jrheum.211318. | 1.0 | 0 |
| 204 | The psoriasis glycome: differential expression of cholesterol particle glycans and IgA glycans linked to disease severity. Journal of Investigative Dermatology, 2022, , . | 0.3 | 0 |
| 205 | 2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. Journal of Rheumatology, 2022, , . | 1.0 | 0 |
| 206 | Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032211100. | 0.3 | 0 |